Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Cancer
BETHESDA, Md--The FDA has approved Burroughs Wellcome's Navelbine (vinorelbine tartrate) for the first-line treatment of ambulatory patients with unresectable, advanced non-small-cell lung cancer (NSCLC).
BETHESDA, Md--The FDA has approved Burroughs Wellcome's Navelbine(vinorelbine tartrate) for the first-line treatment of ambulatorypatients with unresectable, advanced non-small-cell lung cancer(NSCLC).
Navelbine, an intravenous therapy given on an outpatient basis,is the first new drug approved for NSCLC in 20 years. It is indicatedfor use as a single agent for treating patients with stage IVNSCLC and in combination with cisplatin (Platinol) for treatingstage III or IV disease. A fuller report on Navelbine's approvalwill appear in the February issue of ONI.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
